Table 2.

Multivariable outcome analyses in patients with de novo acute myeloid leukemia and sole +8

Variables in final models	Complete remission		Disease-free survival		Overall survival
	P	OR (95% CI)	P	HR (95% CI)	P	HR (95% CI)
Sole +8 AML <60 years
BAALC expression (high vs low)	0.04	0.13 (0.02-0.91)	-	-	-	-
FLT3-ITD (positive vs negative)	-	-	0.054	2.87 (0.98-8.40)	0.02	2.77 (1.19-6.45)
Race (white vs non-white)	-	-	-	-	0.01	0.20 (0.06-0.69)
Sole +8 AML ≥60 years
TET2 (mutated vs wild-type)	0.04	0.15 (0.03-0.91)	0.048	3.87 (1.01-14.78)	0.003	3.94 (1.61-9.68)
RAS (mutated vs wild-type)	-	-	-	-	0.03	0.26 (0.08-0.91)

Abbreviations: FLT3-ITD, internal tandem duplication of the FLT3 gene; OR, odds ratio; HR, hazard ratio; CI, confidence interval.

Notes: We considered 30 patients aged <60 years and 29 patients aged ≥60 years for complete remission (CR) and overall survival (OS) and 18 patients aged <60 years and 20 patients aged ≥60 years for disease-free survival (DFS). An odds ratio less than 1.0 means lower CR rate for the first category listed for the variable. Hazard ratios greater than (less than) 1.0 indicate higher (lower) risk for relapse or death (DFS), or death (OS) for the first category listed for the variables.

Variables considered were those significant at α=0.20 in univariable models, i.e., in patients aged <60 years: for CR, NPM1 (mutated vs wild-type), FLT3-ITD (positive vs negative), BAALC expression (high vs low) and age (10 year increase); for DFS, FLT3-ITD (positive vs negative), hemoglobin (continuous), platelets (50x10⁹/L increase), WBC (50×10⁹/L increase), race (white vs non-white), sex (male vs female) and extramedullary involvement (present vs absent); for OS, FLT3-ITD (positive vs negative), platelets (50×10⁹/L increase), WBC (50×10⁹/L increase), race (white vs non-white), sex (male vs female) and extramedullary involvement (present vs absent). In patients aged ≥60 years: for CR, TET2 (mutated vs wild-type), RUNX1 (mutated vs wild-type), ASXL1 (mutated vs wild-type), miR-155 expression (high vs low), hemoglobin (continuous) and +8 metaphases in bone marrow (≥80% vs <80%); for DFS, NPM1 (mutated vs wild-type), FLT3-ITD (positive vs negative), TET2 (mutated vs wild-type), and RAS (mutated vs wild-type); for OS, TET2 (mutated vs wild-type), IDH2 (mutated vs wild-type), RAS (mutated vs wild-type), miR-3151 expression (high vs low) and sex (male vs female).